Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to identify genes fueling the ailments and use targeted molecular drugs to successfully treat them.
On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.
